CN109641936B - 用于癌症疫苗中的pdl1肽 - Google Patents

用于癌症疫苗中的pdl1肽 Download PDF

Info

Publication number
CN109641936B
CN109641936B CN201780045782.2A CN201780045782A CN109641936B CN 109641936 B CN109641936 B CN 109641936B CN 201780045782 A CN201780045782 A CN 201780045782A CN 109641936 B CN109641936 B CN 109641936B
Authority
CN
China
Prior art keywords
seq
cells
peptide
cancer
peptide fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780045782.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109641936A (zh
Inventor
M·H·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Herlev Hospital
Original Assignee
Herlev Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herlev Hospital filed Critical Herlev Hospital
Publication of CN109641936A publication Critical patent/CN109641936A/zh
Application granted granted Critical
Publication of CN109641936B publication Critical patent/CN109641936B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201780045782.2A 2016-06-21 2017-06-20 用于癌症疫苗中的pdl1肽 Active CN109641936B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16175397.5 2016-06-21
EP16175397 2016-06-21
PCT/EP2017/065122 WO2017220602A1 (en) 2016-06-21 2017-06-20 Pdl1 peptides for use in cancer vaccines

Publications (2)

Publication Number Publication Date
CN109641936A CN109641936A (zh) 2019-04-16
CN109641936B true CN109641936B (zh) 2023-11-28

Family

ID=56363704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045782.2A Active CN109641936B (zh) 2016-06-21 2017-06-20 用于癌症疫苗中的pdl1肽

Country Status (5)

Country Link
US (3) US20200339659A1 (enExample)
EP (1) EP3472180A1 (enExample)
JP (1) JP7267014B2 (enExample)
CN (1) CN109641936B (enExample)
WO (1) WO2017220602A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7267014B2 (ja) 2016-06-21 2023-05-01 アイオー バイオテック エーピーエス 癌ワクチンにおける使用のためのｐｄｌ１ペプチド
US20200339691A1 (en) * 2018-01-15 2020-10-29 Epiaxis Therapeutics Pty Ltd Proteinaceous molecules and uses therefor
IL283165B2 (en) 2018-11-21 2024-12-01 Mayo Found Medical Education & Res Adenoviruses and methods for using adenoviruses
WO2020181402A1 (zh) * 2019-03-10 2020-09-17 胡西木 一种抗肿瘤多肽及其应用
WO2021208106A1 (zh) * 2020-04-18 2021-10-21 北京泽勤生物医药有限公司 一种治疗自身免疫病的融合肽
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034768A2 (en) * 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
CN103917243A (zh) * 2011-10-17 2014-07-09 海莱乌医院 基于pd-l1的免疫疗法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
GB8707398D0 (en) * 1987-03-27 1987-04-29 Coopers Animal Health Biologically active molecules
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
US20120269806A1 (en) 2007-08-21 2012-10-25 The General Hospital Corporation Methods of inducing tolerance
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
JP6042106B2 (ja) 2011-06-10 2016-12-14 株式会社ファンペップ メチオニン・スルホキシドを含む新規ポリペプチド
JP7267014B2 (ja) 2016-06-21 2023-05-01 アイオー バイオテック エーピーエス 癌ワクチンにおける使用のためのｐｄｌ１ペプチド
EP3713645A1 (en) * 2017-11-24 2020-09-30 IO Biotech APS Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034768A2 (en) * 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
CN103917243A (zh) * 2011-10-17 2014-07-09 海莱乌医院 基于pd-l1的免疫疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients;Shamaila Munir,et al.;《Cancer Res》;20130315;第73卷(第6期);摘要，第1765页左栏第1-3段，第1769-1771页全部，图3-6 *
鼠抗人PD-L1功能性单克隆抗体的研制及其生物学特性的鉴定;周莹等;《细胞与分子免疫学杂志》;20111130;第27卷(第11期);第1208-1211页 *

Also Published As

Publication number Publication date
US20250230218A1 (en) 2025-07-17
JP7267014B2 (ja) 2023-05-01
EP3472180A1 (en) 2019-04-24
US12187782B2 (en) 2025-01-07
JP2019527676A (ja) 2019-10-03
WO2017220602A1 (en) 2017-12-28
US20200339659A1 (en) 2020-10-29
CN109641936A (zh) 2019-04-16
US20220372108A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
US12187782B2 (en) PDL1 peptides for use in cancer vaccines
Karbach et al. Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival
JP2546544B2 (ja) 免疫強化を促進するための方法と組成物
JP2010504356A (ja) 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
NO309798B1 (no) Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US20250236658A1 (en) Pdl2 compounds
JP7211938B2 (ja) 免疫原性アルギナーゼペプチド
JP2019517508A (ja) がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン
EP4045150A1 (en) Immunogenic compounds for treatment of adrenal cancer
KR101913333B1 (ko) 신규 ctl 에피토프 4 연결 펩타이드
KR101851666B1 (ko) 신규 ctl 에피토프 5 연결 펩타이드
JP6758185B2 (ja) マルチエピトープｔａｒｐペプチドワクチンおよびその使用
EP4082563A1 (en) Post-operation adjuvant therapy agent
Abu Identification of Glypican3-derived Long Peptides Capable of Inducing both CTL and Th cells and Useful for Immunotherapy of Hepatocellular Carcinoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20370812

TG01 Patent term adjustment